• About
  • Terms of Use
  • Privacy & Policy
  • Cookie policy
  • “press@ustechtimes.com”.
USTechTimes, Magazine & Review WordPress Theme 2017
  • Home
  • topics
    • All
    • AgTech
    • AI
    • Analytics
    • AR/VR
    • Biotech
    • Blockchain
    • Cars / autonomous vehicles
    • Clean tech / environment
    • Cloud infrastructure
    • Cryptocurrency
    • Data services
    • Developer tools
    • E-commerce
    • Education
    • Energy tech
    • Enterprise
    • Entertainment & sports
    • Security
    PartsTech, a Boston-based car component startup, bags $35 million

    PartsTech, a Boston-based car component startup, bags $35 million

    Gradiant raises $225 million in Series D, enters the unicorn club

    Gradiant raises $225 million in Series D, enters the unicorn club

    Ohmium, a green hydrogen startup closes $250 million Series C

    Ohmium, a green hydrogen startup closes $250 million Series C

    Vedanta Biosciences, a clinical-stage company, secured $106.5 million

    Vedanta Biosciences, a clinical-stage company, secured $106.5 million

    Trending Tags

      • Advertising
      • AgTech
      • AI
      • Analytics
      • AR/VR
      • Biotech
      • Blockchain
      • Cars / autonomous vehicles
      • Clean tech / environment
      • Cloud infrastructure
      • Consumer health & fitness
      • Consumer products
      • Cryptocurrency
      • Data services
      • Developer tools
      • Distributed workforce
      • E-commerce
      • Education
      • Energy tech
      • Enterprise
      • Entertainment & sports
      • Fashion
      • Fintech
      • Food and beverage
      • Games
      • Gaming/eSports
      • Govtech
      • Hardware
      • Health & hospital services
      • Health IT
      • Human capital
      • Impact
      • Insurance
      • IoT
      • Local commerce
      • Lodging/hospitality
      • Logistics
      • Manufacturing
      • Marketing automation
      • Marketplaces
      • Material science
      • Media/content
      • Medical devices
      • Messaging
      • Network infrastructure
      • Parenting/families
      • Payments
      • Pharmaceuticals
      • Real estate/proptech
      • Retail
      • Robotics
      • SaaS
      • Sales and CRM
      • Security
      • SMB software
      • Social commerce
      • Social mobile
      • Space
      • Gaming/eSports
      • Travel
      • Games
    • Interview
    • Venture Capital
    No Result
    View All Result
    • Home
    • topics
      • All
      • AgTech
      • AI
      • Analytics
      • AR/VR
      • Biotech
      • Blockchain
      • Cars / autonomous vehicles
      • Clean tech / environment
      • Cloud infrastructure
      • Cryptocurrency
      • Data services
      • Developer tools
      • E-commerce
      • Education
      • Energy tech
      • Enterprise
      • Entertainment & sports
      • Security
      PartsTech, a Boston-based car component startup, bags $35 million

      PartsTech, a Boston-based car component startup, bags $35 million

      Gradiant raises $225 million in Series D, enters the unicorn club

      Gradiant raises $225 million in Series D, enters the unicorn club

      Ohmium, a green hydrogen startup closes $250 million Series C

      Ohmium, a green hydrogen startup closes $250 million Series C

      Vedanta Biosciences, a clinical-stage company, secured $106.5 million

      Vedanta Biosciences, a clinical-stage company, secured $106.5 million

      Trending Tags

        • Advertising
        • AgTech
        • AI
        • Analytics
        • AR/VR
        • Biotech
        • Blockchain
        • Cars / autonomous vehicles
        • Clean tech / environment
        • Cloud infrastructure
        • Consumer health & fitness
        • Consumer products
        • Cryptocurrency
        • Data services
        • Developer tools
        • Distributed workforce
        • E-commerce
        • Education
        • Energy tech
        • Enterprise
        • Entertainment & sports
        • Fashion
        • Fintech
        • Food and beverage
        • Games
        • Gaming/eSports
        • Govtech
        • Hardware
        • Health & hospital services
        • Health IT
        • Human capital
        • Impact
        • Insurance
        • IoT
        • Local commerce
        • Lodging/hospitality
        • Logistics
        • Manufacturing
        • Marketing automation
        • Marketplaces
        • Material science
        • Media/content
        • Medical devices
        • Messaging
        • Network infrastructure
        • Parenting/families
        • Payments
        • Pharmaceuticals
        • Real estate/proptech
        • Retail
        • Robotics
        • SaaS
        • Sales and CRM
        • Security
        • SMB software
        • Social commerce
        • Social mobile
        • Space
        • Gaming/eSports
        • Travel
        • Games
      • Interview
      • Venture Capital
      No Result
      View All Result
      USTechTimes - Leading Startup and Technology News in the United States
      No Result
      View All Result
      Home Pharmaceuticals

      Odyssey Therapeutics bags $168 million to expand its range of cancer drugs

      Odyssey Therapeutics specializes in next-generation precision immunomodulators and oncology medications.

      USTechTimes Editor by USTechTimes Editor
      October 19, 2022
      Odyssey Therapeutics bags $168 million to expand its range of cancer drugs
      Share on FacebookShare on Twitter

      Biotech company Odyssey Therapeutics, Inc. has announced a $168 million Series B financing within ten months of disclosing a $218 million Series A. The round was led by global venture capital firm General Catalyst, an active investor in the healthcare sector.

      Along with Rowe Price Associates, Inc., Fidelity Management & Research Company and T, other Series B fundraising round investors were GreatPoint Ventures, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, and The Healthcare Innovation Investment Fund LLC.

      With the Fresh fundraising, the biotechnology company’s total capital has reached $386 million. The money will be used to expand Odyssey’s range of cancer drugs and precise immunomodulators. It specializes in next-generation precision immunomodulators and oncology medications.

      “Odyssey is pioneering next-generation therapeutics by marrying a powerful drug discovery engine integrating machine learning, biology, and medicinal and structural chemistry with an exceptional leadership team of proven drug developers. We are pleased to partner with a world-class syndicate of investors,” said Gary D. Glick, Ph.D., Founder and Chief Executive Officer of Odyssey Therapeutics.

      The startup is on a mission to develop innovative medicines for serious human ailments

      As the healthtech firm’s narrative moves forward, Glick comments, “We have made remarkable accomplishments since our launch in 2021, and we cherish the support as we push many candidates into IND-enabling tests in 2023.”

      Even before Gary D. Glick disclosed the company, Odyssey Therapeutics had a wealthy syndicate backing it. The company’s $218 million raising in December 2021 completely rocked the market, and it’s continuing at the same rate in 2022.

      The healthtech startup already made its aggressive growth plans known by purchasing quantum machine learning company Rahko in January and making high-profile hires, such as the selection of former Vertex CEO Jeffrey Leiden, M.D., Ph.D., as board chair and Merck veteran Darryl Patrick, Ph.D., as executive vice president of nonclinical development.

      Now that preparations for human trial-enabling research are underway, Odyssey has turned to its original investors to provide funding for the project. General Catalyst led a $168 million series B financing that included investments from additional new investors, such as funds and accounts administered by Fidelity Management & Research Company and T and Rowe Price Partners.

      Odyssey has eight disclosed immunology and cancer initiatives in its portfolio. The portfolio’s current emphasis is on protein and small-molecule therapies. Odyssey will advance several candidates into human trial-enabling studies the following year, indicating that it is still on track to meet its stated goal of starting clinical trials in late 2023 or early 2024.

      “We are confident in Odyssey’s vision, proven leadership and ability to pioneer and develop next generation therapeutics through their integrated platform approach, and we look forward to seeing Odyssey work toward achieving their mission of delivering life-enhancing medicines to patients in need,” said Elena Viboch, Partner at General Catalyst.

      Related Posts

      • Berkeley-based biotechnology startup Carmot Therapeutics raises $160 million in its Series D

        California Berkeley-based clinical-stage biotechnology startup Carmot Therapeutics, Inc. has closed a $160 million Series D…

      • Financial infrastructure innovator Prime Trust raises $100 million in its Series B

        Financial infrastructure innovator Prime Trust has raised over $100 million in a Series B funding…

      • Nuclear Fusion company TAE technologies bags $250 million in its latest funding round

        The promise of clean energy from nuclear fusion continues to fire up investors. TAE Technologies…

      Tags: Biotechcancer drugsHealth TechnologyHealthtech
      USTechTimes Editor

      USTechTimes Editor

      USTechTimes.com is an independent new media site that focuses on the latest technology and digital news in the United States and around the world. The site focuses on new startup launching, startup funding, and development in the startup space.

      Related Posts

      Alto Pharmacy delivers prescriptions medication on the same day.
      Pharmaceuticals

      Alto Pharmacy in talks to go public via Alec Gores’ firm

      May 9, 2021
      No Result
      View All Result

      FREE NEWSLETTER

       

      PRODUCTS

      USTechTimes – Leading Startup and Technology News in the United States

      USTechTimes.com is an independent new media site that focuses on the latest technology and digital news in the United States and around the world. The site focuses on new startup launching, startup funding, and development in the startup space.

      More from our network


      • ktd

      • atd

      • itd

      • ktt

      • kgd

      • kpp

      • ktp

      • kpoppost

      • ustechtimes

      Categories

      • Accelerator
      • Animation
      • Apple
      • Applications
      • Artificial Intelligence
      • Advertising
      • AgTech
      • AI
      • Analytics
      • AR/VR
      • About
      • Terms of Use
      • Privacy & Policy
      • Cookie policy
      • “press@ustechtimes.com”.

      © 2023 ustechtimes.com

      No Result
      View All Result
      • Home
      • topics
        • Advertising
        • AgTech
        • AI
        • Analytics
        • AR/VR
        • Biotech
        • Blockchain
        • Cars / autonomous vehicles
        • Clean tech / environment
        • Cloud infrastructure
        • Consumer health & fitness
        • Consumer products
        • Cryptocurrency
        • Data services
        • Developer tools
        • Distributed workforce
        • E-commerce
        • Education
        • Energy tech
        • Enterprise
        • Entertainment & sports
        • Fashion
        • Fintech
        • Food and beverage
        • Games
        • Gaming/eSports
        • Govtech
        • Hardware
        • Health & hospital services
        • Health IT
        • Human capital
        • Impact
        • Insurance
        • IoT
        • Local commerce
        • Lodging/hospitality
        • Logistics
        • Manufacturing
        • Marketing automation
        • Marketplaces
        • Material science
        • Media/content
        • Medical devices
        • Messaging
        • Network infrastructure
        • Parenting/families
        • Payments
        • Pharmaceuticals
        • Real estate/proptech
        • Retail
        • Robotics
        • SaaS
        • Sales and CRM
        • Security
        • SMB software
        • Social commerce
        • Social mobile
        • Space
        • Gaming/eSports
        • Travel
        • Games
      • Interview
      • Venture Capital

      © 2023 ustechtimes.com